Sigyn Therapeutics (SIGY) Cash from Financing Activities (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Cash from Financing Activities of $284438.0 for Q3 2025, up 103.17% sequentially from $140000.0 in Q2 2025, and up 3.45% YoY from $274956.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Cash from Financing Activities (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Cash from Financing Activities for 10 years, with the latest figure at $284438.0 in Q3 2025.
- Quarterly Cash from Financing Activities rose 3.45% year-over-year to $284438.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $857209.0 (up 5.79% YoY) and the FY2024 annual result came in at $872890.0, down 37.05% from the prior year.
- Cash from Financing Activities rose to $284438.0 in Q3 2025 per SIGY's latest filing, from $140000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $1.5 million in Q2 2021 and troughed at $30000.0 in Q2 2023.
- A 5-year average of $363198.4 and a median of $279697.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2021 and 2023: Cash from Financing Activities soared 3999900.0% in 2021, then plunged 90.67% in 2023.
- Over 5 years, Cash from Financing Activities stood at $400000.0 in 2021, then advanced by 8.0% to $432000.0 in 2022, then plunged by 82.64% to $75000.0 in 2023, then soared by 83.43% to $137574.0 in 2024, then surged by 106.75% to $284438.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $284438.0, $140000.0, and $295197.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 284,438.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 284,438.00 |
| Sep 30, 2025 | 284,438.00 |
| Jun 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 295,197.00 |
| Mar 31, 2025 | 295,197.00 |
| Dec 31, 2024 | 137,574.00 |
| Dec 31, 2024 | 137,574.00 |
| Sep 30, 2024 | 274,956.00 |
| Sep 30, 2024 | 274,956.00 |
| Jun 30, 2024 | 203,600.00 |
| Jun 30, 2024 | 203,600.00 |
| Mar 31, 2024 | 256,760.00 |
| Mar 31, 2024 | 256,760.00 |
| Dec 31, 2023 | 75,000.00 |
| Dec 31, 2023 | 75,000.00 |
| Sep 30, 2023 | 405,000.00 |
| Sep 30, 2023 | 405,000.00 |
| Jun 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 30,000.00 |